Systemic treatment for hepatocellular carcinoma (HCC) has been boosted by the
incorporation of new agents after many negative phase III trials in the decade since the …

Following the discovery that nearly half of all cutaneous melanomas harbour a mutation in
the BRAF gene, molecular targeted kinase inhibitors have been developed for the treatment …

Background Encorafenib plus binimetinib and encorafenib alone improved progression-free
survival compared with vemurafenib in patients with BRAF V600-mutant melanoma in the …

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous
melanoma have been significantly revised over the past few years in response to emerging …

Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical
outcomes in patients with melanoma by preventing or delaying the onset of resistance …

Importance The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell
histiocytosis (LCH) are highly enriched forBRAFV600 mutations and have been previously …

Summary Background Combined BRAF-MEK inhibitor therapy is the standard of care for
BRAF V600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor …

Summary Background Activating BRAF V600E (Val600Glu) mutations are found in about 1–
2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in …

Background Primary analysis of the phase 3 IMspire150 study showed improved
investigator-assessed progression-free survival with first-line atezolizumab, vemurafenib …

Background The cardiovascular complications of cancer therapeutics are the focus of the
burgeoning field of cardio‐oncology. A common challenge in this field is the impact of …